The rapid rise of AI in drug discovery brings both unprecedented opportunities and complex challenges. From accelerating the development of better therapies to navigating the proliferation of tools and technologies, the path forward requires clarity, precision, and innovation. For small biotech companies, this moment also raises a critical question: how can we stay competitive with limited resources?
At ACS Spring 2025, our Co-founder & CEO Josh Haimson will explore these questions across two sessions that highlight the evolving role of AI in the discovery and development of new medicines.
Sunday, March 23
Unlocking a New Era: How AI is Transforming Drug Discovery and Development
A panel moderated by Maria-Jesus Blanco (Atavistik Bio)
- 10:45 AM – 11:30 AM PST
- Ballroom 20D, San Diego Convention Center
Monday, March 24
Competing with Goliaths: A Novel Pre-Competitive ADMET ML Consortium Accelerating Drug Discovery in Biotech Companies
- 4:35 PM – 5:00 PM PST
- Room 7B, San Diego Convention Center
These sessions will examine how AI is redefining medicinal chemistry, the value of pre-competitive ML consortium, and how biotechs can effectively adopt these tools to drive innovation.
Interested in meeting at ACS? Book time with us here.
Inductive Bio Raises $25M Series A to Transform Small Molecule Drug Discovery with Industry-Wide AI Platform
Inductive Bio Announces Publication of Successful Drug Optimization Collaboration with Nested Therapeutics
